Pieris Pharmaceuticals
company
About
Pieris Pharmaceuticals is a clinical-stage biotechnology company applying its proprietary.
- 101 - 250
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $17.30M
- Industries
- Biopharma,Biotechnology,Pharmaceutical
- Founded date
- Jan 1, 2001
- Number Of Employee
- 101 - 250
- Operating Status
- Active
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company applying its proprietary Anticalin® technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.Anticalins are recombinantly engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalins can virtually bind to any target of interest.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$49.30M
Pieris Pharmaceuticals has raised a total of
$49.30M
in funding over 2 rounds. Their latest funding was raised on
Jun 25, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 25, 2021 | Grant | $17.30M | 1 |
Bavarian Ministry of Economic Affairs, Energy and Technology
|
— | Detail |
| Nov 10, 2019 | Post-IPO Equity | $32M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Pieris Pharmaceuticals is funded by 2 investors.
Bavarian Ministry of Economic Affairs, Energy and Technology
and Aquilo Capital Management
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Bavarian Ministry of Economic Affairs, Energy and Technology
|
Yes | Grant |
Aquilo Capital Management
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
